Food–drug interactions in the summary of product characteristics of proprietary medicinal products M Teresa San MiguelJ Alfredo MartínezEmilio Vargas Special Article 11 March 2005 Pages: 77 - 83
Designing the most favourable study design Silvio Garattini Special Article 11 March 2005 Pages: 85 - 86
Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial Thomas Elung-JensenJens HeisterbergAnne-Lise Kamper Clinical Trials 11 March 2005 Pages: 87 - 96
Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population Aurel C. AllabiYves HorsmansJean-Luc Gala Pharmacogenetics 04 February 2005 Pages: 97 - 102
Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers M. ValleM. J. BarbanojM. Brunner Pharmacokinetics and Disposition 12 February 2005 Pages: 103 - 111
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects Agneta WennerholmAnnika AllqvistLeif Bertilsson Pharmacokinetics and Disposition 02 April 2005 Pages: 113 - 118
Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies Espen MoldenBeate Hennie GarciaAnne Elise Eggen Pharmacoepidemiology and Prescription 04 February 2005 Pages: 119 - 125
The application of prescribing indicators to a primary care prescription database in Ireland D. WilliamsK. BennettJ. Feely Pharmacoepidemiology and Prescription 12 February 2005 Pages: 127 - 133
Incidence of drug-induced liver injury in medical inpatients Yvonne MeierMarzia CavallaroKarin Fattinger Pharmacoepidemiology and Prescription 23 February 2005 Pages: 135 - 143
Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study Willeke N. KasjePetra DenigFlora M. Haaijer-Ruskamp Pharmacoepidemiology and Prescription 11 March 2005 Pages: 145 - 151
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients Eric DaillyVéronique ReliquetPascale Jolliet Short Communication 11 March 2005 Pages: 153 - 156
Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib Stefan R. FlorentinusMerete W. NielsenEibert R. Heerdink Short Communication 11 March 2005 Pages: 157 - 159
Publication bias in complementary and conventional medicine Alfredo VannacciClaudia RavaldiFiammetta Cosci Letter to the Editors 11 March 2005 Pages: 161 - 162
In response to Vannacci, “Publication bias in complementary and conventional medicine” E ErnstK Schmidt Letter to the Editors 19 March 2005 Pages: 163 - 163
Clinical trials of medication in children, 1996–2002 HM SammonsI Choonara Letter to the Editors 11 March 2005 Pages: 165 - 167